Glenmark Pharmaceuticals Ltd. saw its shares climb by 3% in Thursday's trading session following the announcement that it has received approval from the U.S. Food and Drug Administration (USFDA) for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray.
The global, research-led pharmaceutical firm confirmed that its product is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray, manufactured by Haleon US Holdings LLC.
Market Impact and Product Distribution
The approval marks a significant development for Glenmark, as the company plans to distribute the product in the U.S. through Glenmark Pharmaceuticals Inc., USA. According to IQVIA sales data for the 12-month period ending June 2026, the market for Flonase Nasal Spray recorded substantial annual sales of approximately $295.2 million, indicating a lucrative opportunity for Glenmark's generic offering.
Following the positive news, Glenmark Pharmaceuticals' shares rose 2.52%, hitting a high of Rs 2,321 apiece. The stock has demonstrated a strong performance year-to-date, gaining 14.79% against a 9.10% fall in the Sensex during the same period.
Executive Commentary and Company Profile
Marc Kikuchi, President and Business Head, North America, commented on the approval, stating, "The approval of Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray marks another step in expanding our respiratory portfolio in the U.S. and builds on the strong foundation we have established in this therapeutic area. We remain committed to broadening access to quality, affordable treatment options that address the evolving needs of patients and healthcare providers."
Glenmark Pharma operates 11 manufacturing facilities across four continents and is supported by six R&D centers globally. With a commercial footprint spanning over 80 countries, the company offers a diversified portfolio that includes branded, innovative, generics, and consumer health products, with a strategic focus on respiratory, dermatology, and oncology therapeutic areas. Glenmark is recognized among the top 100 biopharmaceutical companies worldwide by pharmaceutical sales.